Participants with small cell lung cancer with brain metastases for Small Cell Lung Carcinoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Memorial Sloan Kettering Nassau, Rockville Centre, NY
Small Cell Lung Carcinoma+9 More
Cerebrospinal fluid collection - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

Eligible Conditions

  • Small Cell Lung Carcinoma
  • Tumors Metastatic to Brain
  • Brain Metastases, Adult
  • Small-cell Lung Cancer
  • Metastatic Lung Cancer
  • Lung Cancers

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Small Cell Lung Carcinoma

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 6 months

6 months
Overall survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Small Cell Lung Carcinoma

Trial Design

1 Treatment Group

Participants with small cell lung cancer with brain metastases
1 of 1
Experimental Treatment

62 Total Participants · 1 Treatment Group

Primary Treatment: Participants with small cell lung cancer with brain metastases · No Placebo Group · Phase 2

Participants with small cell lung cancer with brain metastasesExperimental Group · 2 Interventions: Cerebrospinal fluid collection, Stereotactic Radiosurgery · Intervention Types: Procedure, Radiation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cerebrospinal fluid collection
2015
N/A
~220
Stereotactic Radiosurgery
2012
Completed Phase 2
~320

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: Memorial Sloan Kettering Nassau · Rockville Centre, NY
2020First Recorded Clinical Trial
9 TrialsResearching Small Cell Lung Carcinoma
36 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a histologic diagnosis of small cell lung cancer.
You have at least 10 brain metastases on contrast-enhanced MRI.
You have a performance status of 60-100/ECOG 0-2.
You are female and of reproductive potential or have a negative serum pregnancy test at the time of enrollment.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.